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Abstract

Author Manuscript

New antibacterial agents with novel target and mechanism of action are urgently needed to combat
problematic bacterial infections and mounting antibiotic resistances. Topoisomerase IA represents
an attractive and underexplored antibacterial target, as such, there is a growing interest in
developing selective and potent topoisomerase I inhibitors for antibacterial therapy. Based on our
initial biological screening, fluoroquinophenoxazine 1 was discovered as a low micromolar
inhibitor against E. coli topoisomerase IA. In the literature, fluoroquinophenoxazine analogs have
been investigated as antibacterial and anticancer agents, however, their topoisomerase I inhibition
was relatively underexplored and there is little structure-activity relationship (SAR) available. The
good topoisomerase I inhibitory activity of 1 and the lack of SAR prompted us to design and
synthesize a series of fluoroquinophenoxazine analogs to systematically evaluate the SAR and to
probe the structural elements of the fluoroquinophenoxazine core toward topoisomerase I enzyme
target recognition. In this study, a series of fluoroquinophenoxazine analogs was designed,
synthesized, and evaluated as topoisomerase I inhibitors and antibacterial agents. Target-based
assays revealed that the fluoroquinophenoxazine derivatives with 9-NH2 and/or 6-substituted
amine functionalities generally exhibited good to excellent inhibitory activities against
topoisomerase I with IC50s ranging from 0.24–3.9 µM. Notably, 11a bearing the 6methylpiperazinyl and 9-amino motifs was identified as one of the most potent topoisomerase I

Author Manuscript

*

Corresponding author. Dr. Dianqing Sun, Department of Pharmaceutical Sciences, The Daniel K. Inouye College of Pharmacy,
University of Hawai’i at Hilo, 34, Rainbow Drive, Hilo, HI 96720, USA., Tel: +1-(808)-933-2960, Fax: +1-(808)-933-2974,
dianqing@hawaii.edu (D. Sun).
1These two authors contributed equally to this paper.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Conflict of interest
The authors declare no conflict of interest.
Appendix A: Supplementary data
Supplementary data related to this article can be found at

Yu et al.

Page 2

Author Manuscript

inhibitors (IC50 = 0.48 µM), and showed broad spectrum antibacterial activity (MICs = 0.78–7.6
µM) against all the bacteria strains tested. Compound 11g with the 6-bipiperidinyl lipophilic side
chain exhibited the most potent antituberculosis activity (MIC = 2.5 µM, SI = 9.8). In addition,
CoMFA analysis was performed to investigate the 3D-QSAR of this class of
fluoroquinophenoxazine derivatives. The constructed CoMFA model produced reasonable
statistics (q2 = 0.688 and r2 = 0.806). The predictive power of the developed model was obtained
using a test set of 7 compounds, giving a predictive correlation coefficient r2pred of 0.767.
Collectively, these promising data demonstrated that fluoroquinophenoxazine derivatives have the
potential to be developed as a new chemotype of potent topoisomerase IA inhibitors with
antibacterial therapeutic potential.

Graphical Abstract
Author Manuscript
Keywords
Antibacterial; CoMFA analysis; 3D-QSAR; fluoroquinophenoxazine; topoisomerase IA; SAR

1. Introduction
Author Manuscript

DNA topoisomerases maintain the helical and superhelical structure of DNA and are
essential enzymes required for cellular processes and functions including DNA replication,
transcription, and repair [1, 2]. Therefore, poison inhibitors of topoisomerase enzymes can
lead to the accumulation of the intermediate topoisomerase-DNA cleavage complex and
subsequently result in bacterial or cancer cell death [2, 3]. Clinically, topoisomerase
enzymes represent attractive and successful targets for anticancer and antibacterial
chemotherapy [4, 5]. In contrast, topoisomerase I is underexplored as antibacterial target,
thus potent and selective topoisomerase I inhibitors can serve as a promising class of
chemotherapeutic agents toward the treatment of problematic bacterial infections [6, 7].

Author Manuscript

In our ongoing efforts to discover new topoisomerase I inhibitors as antibacterial agents and
to probe the topoisomerase I recognition [8, 9], we identified during high-throughput
screening (HTS) assay development a compound NSC648059 (1, Fig. 1) with low
micromolar inhibitory activity (IC50 = 0.8–2.0 µM) against Escherichia coli topoisomerase I.
Structurally, 1 is a fluoroquinophenzoxazine derivative with a unique planar tetracyclic ring
system, belonging to a member of an extended chemical class of fluoroquinolone antibiotics.
In the clinic, fluoroquinolones including norfloxacin and ciprofloxacin (Fig. 1) represent
some of the most successful antibiotic classes, whose mechanisms of action are to inhibit
bacterial DNA gyrase and topoisomerase IV as well as relaxation of supercoiled DNA and
thus to promote breakage of double-stranded DNA [10]. Specifically,
Eur J Med Chem. Author manuscript; available in PMC 2018 January 05.
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fluoroquinophenoxazines such as A-62176 and A-85226 (Fig. 1) have been reported as
antibacterial [11, 12] and anticancer [13–16] agents. For example, A-62176 exhibited good
activity against several cancer cell lines with IC50 values ranging from 0.87–4.34 µM [13].
However, their bacterial topoisomerase I inhibition was relatively underexplored and there is
little structure-activity relationship (SAR) of fluoroquinophenoxazine derivatives available
in the literature [13]. Herein, on the basis of this HTS hit 1, we describe the design,
synthesis, and evaluation of a series of fluoroquinophenoxazine structural analogs, probing
their SAR toward bacterial topoisomerase I and other topoisomerases as well as their whole
cell antibacterial activity. Additionally, we built and developed a quantitative structureactivity relationship (QSAR) and comparative molecular field analysis (CoMFA) model in
an effort to guide further design and synthesis of this class of topoisomerase IA inhibitors.

2. Results and discussion
Author Manuscript

2.1. Chemistry

Author Manuscript

To validate the initial assay hit, we first resynthesized 9-amino-5, 6-difluoro-3-oxo-3H–
pyrido[3,2,1-kl] phenoxazine-2-carboxylic acid (1) and retested its biochemical activity
against E. coli topoisomerase I. Resynthesized fluoroquinophenoxazine hit 1 showed
reproducible topoisomerase I inhibitory activity with an IC50 of 1.95 µM. The synthesis of 1
is shown in Scheme 1. Briefly, commercially available 2,3-difluoro-6-nitrophenol was
hydrogenated using Pd/C (20 mol %) as the catalyst to the corresponding amino product 2,
which can be used in next step without further purification [17]. Subsequent reaction of the
aniline derivative 2 with diethyl 2-(ethoxymethylene)malonate under ambient temperature
gave 3 in 87% yield. For next nucleophilic displacement cyclization, an improved protocol
was developed for this intramolecular cyclization reaction under microwave irradiation at
250 °C instead of conventional heating [11]. Following simple filtration, 4 was obtained in
80% yield. Subsequently, 4 reacted with 1-chloro-2,4-dinitrobenzene (5a) in DMF at 100 °C
to give the desired tetracyclic product 6a in 57% yield. Upon treatment of 6a in acidic
condition (AcOH/HCl) under reflux for 4 h, the free carboxylic acid derivative 7a was
obtained by simple filtration in 91% yield. Finally, hydrogenation of 7a under H2 (1.0 bar)
using FeSO4·6H2O as the catalyst failed to yield the amine product 1 after 14 h. However,
when SnCl2 was used as catalyst and AcOH as the solvent, the nitro group was smoothly
reduced into the amino group under reflux for 3 h and the final product 1 was obtained in
86% yield.

Author Manuscript

Under the optimized conditions, we next expanded the structural diversity of 1 to evaluate
the effect of various substituents on the quinophenoxazine skeleton and to explore their
SAR. First, we used various substrates 5b–e in Scheme 2 in an effort to generate a focused
set of quinophenoxazine derivatives 7b–e. It is worthwhile noting that a dramatic difference
was observed in terms of the reactivity of the substrate 5 with different electronic and/or
physiochemical properties. For example, 5b bearing an electron-withdrawing nitrile group
facilitated the completion of cyclization in 2 h and 6b was obtained in 59% yield. On the
other hand, 5c with the lipophilic trifluoromethyl group could finish the reaction by
extending the reaction time, affording the desired product 6c in a lower yield (10%). In
addition, when the substrate 5d with an acetyl group was tried, 6d was obtained in 38%

Eur J Med Chem. Author manuscript; available in PMC 2018 January 05.
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yield. However, for the substrate with the corresponding fluorine substitution, no reaction
occurred even when the reaction temperature was raised to 120 °C. Furthermore, more harsh
conditions were tried in an attempt to facilitate the reaction by heating the reaction to 160 °C
in a sealed pressure tube or heating the reaction to 200 °C under microwave irradiation, but
with not much success. In the case of 5e with additional nitro and chlorine substituents, the
reaction proceeded smoothly and 6e was obtained in 40% yield. Final ester hydrolysis was
performed in acetic acid/hydrochloric acid under reflux, affording free carboxylic acid
products 7b–e in 36–95% yields.

Author Manuscript
Author Manuscript

In the course of antibacterial evaluation, we observed compound 1 lost 2–4 fold whole cell
antibacterial activity after 4 weeks of storage, indicating that 1 may have stability and/or
solubility issue. From our 1H NMR experiments, we also noted that 1 could be easily
precipitated out in d6-DMSO solvent and no degradation-related evidence was observed
following several weeks of monitoring 1 in both d6-DMSO NMR and HPLC experiments
(data not shown). Thus, to enhance the overall solubility profile of this class of
quinophenoxazine derivatives, we introduced a variety of solubilizing and polar groups into
the fluoroquinophenoxazine scaffold by displacing the 6-fluorine atom of 6a, 7a, or 1 with
different amine functionalities such as piperazine, 1-methylpiperazine, and morpholine
(Scheme 3) [18]. Specifically, 6a reacted with 1-methylpiperazine in pyridine at 110 °C to
give 9 in 53% yield. Accordingly, 7a reacted with 1-methylpiperazine and piperazine in
pyridine under nitrogen atmosphere at 90 °C, and both reactions proceeded smoothly to
afford 10a and 10b in 45% and 84% yields, respectively [12]. In the cases of 1 and some
other amine substrates, notably, reaction temperature appeared to play a critical role in this
nucleophilic displacement reaction. For example, when morpholine was used as a
nucleophile, the reaction became complicated under 90 °C, which is suitable for 1methylpiperazine and piperazine. In contrast, when temperature was reduced to 70 °C, the
reaction could be completed in 16 h to produce 11d in 71% yield. Other functional amines
were also subjected to this substitution reaction, and most of the reactions could lead to the
desired products 11c–k under 90 °C in moderate yields except for 1-adamantylamine. We
found that the reaction of 1 with 1-adamantylamine could finish under reflux after 4 days in
29% yield, presumably due to steric effect. In addition, to investigate the effect of the free
amine functionality of 1 on topoisomerase inhibition and antibacterial activity, we next tried
to protect the free amino group with acetyl functionality. The N-acetyl derivative 12 was
synthesized from 1 and acetic anhydride in pyridine at 80–100 °C and the solid product was
collected by simple filtration in high yield (92%).

Author Manuscript

Finally, to evaluate the potential stereospecific effect at the 6 position of
fluoroquinophenoxazine derivatives on biological activity, we designed and synthesized
several chiral fluoroquinophenoxazine amine derivatives from 6a or 1 and chiral amine
building blocks [12, 13]. The nucleophilic substitution reaction of 1 and (S)-3-(Bocamino)pyrrolidine (13a) in pyridine was completed in 20 h, affording 15a in 86% yield.
Subsequent N-Boc deprotection of 15a produced 17a in 78% yield upon the treatment with
diluted hydrochloric acid. With regard to the reaction of 1 and the corresponding (R)-3(Boc-amino)pyrrolidine (13b), the substituted compound 15b could not be obtained by
filtration upon the completion of reaction. Therefore, the crude product 15b was used for the

Eur J Med Chem. Author manuscript; available in PMC 2018 January 05.
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following deprotection reaction and the corresponding fluorophenoxazine derivative 17b (R)
was obtained in 48% yield over two steps. Accordingly, compound 16 was synthesized from
6a as the starting material in 32% yield over two steps (Scheme 4).
2.2. Biological testing
All the synthesized target molecules were tested for the ability to inhibit the relaxation
activity of E. coli topoisomerase I in target-based assay, as well as against a panel of
bacterial strains including the wild-type E. coli MG1655 K12 strain, E. coli strain BAS3023
with imp mutation conferring membrane permeability to small molecules [19, 20], the wildtype Gram-positive B. subtilis (ATCC 6633) strain, and M tuberculosis (H37Rv). The results
are summarized in Table 1.

Author Manuscript
Author Manuscript
Author Manuscript

2.2.1. E. coli topoisomerase I inhibition—Biochemical evaluation for inhibition of the
relaxation activity of E. coli topoisomerase I revealed that the majority of our synthesized
compounds possessed good activity against E. coli topoisomerase I. On the basis of these
topoisomerase I inhibition data (Table 1), an illuminating SAR has been obtained and is
summarized in Fig. 2. i). The 9 position substituent plays a very important role in
topoisomerase I inhibitory activity. Among the 5,6-difluoroquinophenoxazine derivatives,
the hit compound 1 with the electron-donating 9-NH2 group showed the most potent activity
(IC50 = 195 µM) against E. coli topoisomerase I. Both free carboxylic acid 7c and its ethyl
ester derivative 6c with the 9-CF3 functionality were inactive against topoisomerase I when
tested at 125 µM. In addition, compared to 1 (9-NH2, 1.95 µM), all the other 5,6-difluoro
derivatives with 9-substituted electron-withdrawing groups (7a with 9-NO2, 15.6 µM; 7b
with 9-CN, 31.25 µM; 7d with 9-Ac, 15.6 µM; 7e with 9-NO2 and 10-Cl, 31.25 µM) were
8–16 fold less active with IC50 values ranging from 15.6–31.25 µM. ii). In general, the basic
amine functionality at the 6 position significantly enhanced topoisomerase I inhibitory
activity. For example, the 6-substituted amine derivatives 11a with 6-methylpiperazinyl, 11b
with piperazinyl, 11d with morpholino, 11g with bipiperidinyl, 11h with morpholinoethyl,
as well as the 6-substituted aminopyrrolidinyl derivatives 16, 17a, and 17b demonstrated the
most potent topoisomerase I inhibitory activity with IC50 values of 0.24–0.97 µM; and
within this group, 11d and 11h with the morpholino group had an IC50 value of 0.97 µM. In
contrast, all the other 6-substituted amine derivatives with a more lipophilic side chain,
including 11c with methylpiperidinyl, 11e with phenethyl, 11f with adamantanyl, 11i with
cyclohexyl, 11j with cyclopentyl, 11k with n-hexyl, and 15a with t-Boc-aminopyrrolidinyl,
showed weaker topoisomerase I inhibition with IC50 values ranging from 3.9 to 15.6 µM.
Notably, both 6-substituted aminopyrrolidinyl S- and R- stereoisomers 17a and 17b
exhibited the same topoisomerase I inhibitory activity (IC50 = 0.48–0.97 µM), suggesting the
stereochemistry at the 6 position is not required for topoisomerase I inhibition. iii)
Esterification of the carboxylic acid group had little effect on the E. coli topoisomerase I
inhibitory activity by comparing 6a and 7a (IC50 = 15.6 µM), 6b and 7b (IC50 = 31.25 µM),
as well as 6c and 7c (IC50 >125 µM), indicating the ethyl ester functionality is tolerated for
topoisomerase I enzyme inhibition. Representative inhibition results of 11a and 11b against
E. coli topoisomerase relaxation activity are shown in Fig. 3.

Eur J Med Chem. Author manuscript; available in PMC 2018 January 05.
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2.2.2. Selectivity and specificity against other DNA topoisomerase enzymes—
In addition, to determine the selectivity and specificity profiles of this class of
fluoroquinophenoxazine derivatives, selected compounds were also investigated for the
ability to inhibit other DNA topoisomerases including E. coli DNA gyrase as well as human
topoisomerase I and IIα enzymes. Overall, these compounds were more selective toward E.
coli topoisomerase I than other enzymes tested. Given that this series of compounds has
close structural similarity to quinolone antibiotic class, as such, inhibition against E. coli
gyrase can be also observed. Specifically, most of the compounds showed 4–64 fold
selectivity toward topoisomerase I over DNA gyrase except that the moderately active
compound 7e with the 9-NO2 and 10-chloro substituents showed less specificity with 2 fold
selectivity toward topoisomerase I. With respect to human topoisomerases I and IIα
inhibition, these compounds also showed inhibitory activity against both human
topoisomerase I (IC50 = 3.9–31.25 µM) and topoisomerase IIα (IC50 = 0.97–250 µM), with
approximate 4–32 fold selectivity. Taken together, compounds 11a (IC50 = 0.48 µM) and
11b (IC50 = 0.24 µM) (Fig. 3) bearing both 9-NH2 and 6-piperazinyl motifs exhibited the
most potent topoisomerase I inhibitory activity with the more favorable selectivity profile
(8–64 fold) toward E. coli topoisomerase I against all the other enzymes tested.

Author Manuscript
Author Manuscript

2.2.3. Cell-based antibacterial activity—In addition to target-based topoisomerase
enzyme inhibition, whole cell antibacterial activities of the synthesized compounds were
also assessed against a panel of bacterial strains. The results are also shown in Table 1. From
these data, the majority of these fluoroquinophenoxazine derivatives exhibited good to
excellent antibacterial activity against the membrane permeable E. coli strain BAS3023 and
Gram-positive B. subtilis strain, and were inactive against the wide type E. coli strain.
Additionally, the antibacterial activity of most fluoroquinophenoxazine derivatives (e.g., 1,
7a, 7c, 9, 10a, 11a–d, 11f–i, 15a, 16, and 17a–b) generally correlated with E. coli
topoisomerase I inhibitory activity, suggesting that the antibacterial basis of these
compounds may be in part due to the inhibition of topoisomerase I. The only type IA
topoisomerase present in M. tuberculosis has recently been validated as an antitubercular
target [21]. The topoisomerase I activity has been shown to be essential for viability and
infection in a murine model of tuberculosis [21, 22]. To further determine the
antituberculosis profile for this chemical class of fluoroquinophenoxazine derivatives,
twelve compounds were selected and evaluated against M. tuberculosis. Among them, 11g
with the 6-bipiperidinyl lipophilic side chain and 11d with the 6-morpholino heterocyclic
ring system showed the most potent antituberculosis activity with minimum inhibitory
concentration (MIC) values of 2.5 and 3.5 µM, respectively. In addition, compared to 11d,
its corresponding 6-piperazinyl structural analogs 11a with tertiary amine and 11b with
secondary amine functionality was about 2- and 8-fold less active with the MIC values of 7.6
and 29.5 µM, respectively. In contrast, both 6-substituted aminopyrrolidinyl derivatives 17a
(S) and 17b (R) with primary amine functionality were not active (MIC > 63.1 µM) against
M. tuberculosis. These data strongly suggest that the decreased or lost whole cell
antituberculosis activity of these compounds are most likely due to their decreased
lipophilicity and subsequent cell membrane penetration. Unfortunately, cytotoxicity
evaluation of our tested compounds against healthy normal Vero cells showed that they
generally had narrow selectivity index, with 11g (SI = 9.8) being the most promising
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compound. It is also worthwhile noting that, one of the most potent topoisomerase I
inhibitors, 11a (IC50 = 0.48 µM) bearing the 6-methylpiperazinyl and 9-amino motifs,
showed broad spectrum antibacterial activity against all the test bacteria strains with MICs
ranging from 0.78 to 7.6 µM (SI = 3.8–37).
2.3. CoMFA analysis

Author Manuscript

To further understand the structural basis for topoisomerase I inhibitory activity of this set of
fluoroquinophenoxazine derivatives, we subsequently performed three dimensional QSAR
(3D-QSAR) study using CoMFA analysis [23]. Because of the relatively rigid core structural
feature of this class of fluoroquinophenoxazine molecules, we directly applied core structure
based alignment to build reliable 3D-QSAR models. The CoMFA study was carried out
using a total of 21 compounds (entries 1–21, Table 2). Statistical parameters of the CoMFA
model showed a reasonable cross-validated correlation coefficient q2 of 0.688, indicating a
good internal prediction of the model. The CoMFA model also exhibited a conventional
correlation coefficient r2 of 0.806. To evaluate the predictive ability of our developed model,
a test set of 7 compounds (entries 22–28, Table 2) which was not included in model
generation was subsequently used. The predicative correlation coefficient r2pred of 0.767
indicates good external predicative ability of the CoMFA model. The experimental and
predicted values as well as their residuals from the training and test set molecules are listed
in Table 2. The correlation between the predicted and experimental values of all compounds
was plotted and the resulting chart is shown in Fig. 4.

Author Manuscript

The results of the CoMFA model were analyzed and visualized using the standard deviation
coefficient (StDev*Coeff) mapping option contoured by steric and electrostatic
contributions. In order to probe the structure/activity correlation, the steric and electrostatic
contours were mapped onto their aligned chemical structures of these
fluoroquinophenoxazine molecules to identify the potential regions in which the molecules
would favorably or unfavorably interact with the topoisomerase I enzyme. The
representative steric and electrostatic contour maps of the most active compound 11b and
the least active 6c derived from the CoMFA model are shown in Fig. 5. Briefly, the yellow
areas in the steric contour maps indicate regions of steric hindrance to activity, while the
green areas indicating steric contribution to potency. From the electrostatic contour maps,
the regions in blue indicate positive electrostatic charge potential associated with increased
activity, with the red regions show electronegative groups with increased activity.

Author Manuscript

In Fig. 5A and Fig. 5B, one green contour was found near the piperazinyl moiety of
compound 11b indicating that a moderate steric substituent would be favored at the 6
position of the quinophenoxazine scaffold. This may offer a potential explanation why the 6substituted amino derivatives were generally more active than the 6-fluoro analogs. In
addition, two yellow contours were observed near the 9 position of inactive 6c, indicating
that a steric bulkiness (e.g., NO2 in 6a and 7a, CF3 in 6c, and the acetyl group in 7d) would
be disfavored for activity in this area.
The CoMFA electrostatic contour maps are displayed in Fig. 5C and Fig. 5D. A large blue
contour was found around the 9 position of compounds 11b and 6c, indicating that the
presence of electron rich functionalities and positively charged environment at this position
Eur J Med Chem. Author manuscript; available in PMC 2018 January 05.
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(e.g., NH2 vs. NO2, Ac, CN, and CF3) would be strongly favored for topoisomerase I
inhibitory activity. It was also observed that a big red contour region was present around the
2 position of fluoroquinophenoxazine scaffold, suggesting that an electronegative group
(e.g., COOH and COOR2) at this position may be required for activity. Finally, two red
contours were found at both sides of the fused heterocyclic skeleton of 11b and 6c,
suggesting that electron deficient functionalities would be favored in those regions.

3. Conclusions

Author Manuscript
Author Manuscript

On the basis of a HTS hit compound 1, a series of fluoroquinophenoxazine analogs were
designed, synthesized, and evaluated as topoisomerase IA inhibitors and antibacterial agents.
Among the newly produced fluoroquinophenoxazine derivatives, compounds with the 9NH2 and/or 6-substituted amine functionalities exhibited good to excellent inhibitory
activities against E. coli topoisomerase IA with IC50 values ranging from 0.24 to 3.9 µM. An
illuminating SAR against E. coli topoisomerase I has also been obtained. For example, the
6-substituted amino motif significantly enhanced the topoisomerase I inhibition and the 9NH2 functionality was the most desirable compared to some other groups evaluated.
Notably, 11a bearing the 6-methylpiperazinyl and 9-amino motifs showed excellent
topoisomerase I inhibition (IC50 = 0.48 µM) as well as broad spectrum antibacterial activity
against all the bacteria strains tested with MICs ranging from 0.78 to 7.6 µM (SI = 3.8–37).
In addition, compound 11g with the 6-bipiperidinyl lipophilic side chain represents a
promising antitubercular lead with the most potent antituberculosis activity (MIC = 2.5 µM,
SI = 9.8). Finally, CoMFA analysis was performed to investigate the 3D-QSAR. The
constructed CoMFA model produced reasonable statistics, with q2 = 0.688 and r2 = 0.806.
The predictive power of the developed model was obtained using a test set of 7 molecules,
giving predictive correlation coefficient r2pred of 0.767. Collectively, this work has generated
valuable SAR and critical understanding for this chemotype class of
fluoroquinophenoxazine topoisomerase I inhibitors as antibacterial agents. Our developed
CoMFA model can provide important structural insights toward topoisomerase I recognition
and guide future structure based design and synthesis of bacterial topoisomerase I inhibitors.

4. Experimental
4.1. General methods for chemistry

Author Manuscript

All reagents and anhydrous solvents were purchased from Sigma-Aldrich and Fisher
Scientific, and were used without further purification. All reactions were monitored either by
thin-layer chromatography (TLC) or by analytical high performance liquid chromatography
(HPLC) to detect the completion of reactions. TLC was performed using glass plates precoated with silica gel (0.25 mm, 60-Å pore size, 230–400 mesh, Sorbent Technologies, GA)
impregnated with a fluorescent indicator (254 nm). TLC plates were visualized by exposure
to ultraviolet light (UV). Hydrogenation reactions were performed employing domnick
hunter NITROX UHP-60H hydrogen generator, USA. Microwave synthesis was performed
using Biotage Initiator 8 Exp Microwave System. Compounds were purified by flash column
chromatography on silica gel using a Biotage Isolera One system and a Biotage SNAP
cartridge. 1H and 13C NMR spectra were obtained on a Bruker Avance DRX-400 instrument
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with chemical shifts (d, ppm) determined using TMS as internal standard. Coupling
constants (J) are in hertz (Hz). ESI mass spectra in either positive or negative mode were
provided by Varian 500-MS IT Mass Spectrometer. High-resolution mass spectra (HRMS)
were obtained on an Agilent 6530 Accurate Mass Q-TOF LC/MS. The purity of compounds
was determined by analytical HPLC using a Gemini, 3 µm, C18, 110 Å column (50 mm ×
4.6 mm, Phenomenex) and a flow rate of 1.0 mL/min. Gradient conditions: solvent A (0.1%
trifluoroacetic acid in water) and solvent B (acetonitrile): 0–2.00 min 100% A, 2.00–7.00
min 0–100% B (linear gradient), 7.00–8.00 min 100% B, UV detection at 254 and 220 nm.

Author Manuscript

4.1.1. 6-Amino-2,3-difluorophenol (2)—2,3-Difluoro-6-nitrophenol (700 mg, 4 mmol)
was dissolved in ethanol (5 mL) and palladium on activated carbon (Pd/C) (84.8 mg, 20%)
was added. The reaction was stirred at room temperature under H2 atmosphere (1.0 bar).
After 7 h, all starting material was consumed and Pd/C was filtered through Celite. The
solvent was evaporated under reduced pressure to afford 6-amino-2,3-difluorophenol (550.5
mg, 95% yield). 1H NMR (400 MHz, CDCl3): δ (ppm) 6.59 (dt, J = 9.9, 8.6 Hz, 1H), 6.47–
6.31 (m, 1H), 4.27 (br s, 2H). ESI-HRMS: calc. for C6H6F2NO [M + H]+: 146.0412, found:
146.0418.

Author Manuscript

4.1.2. Diethyl 2-(((3,4-difluoro-2-hydroxyphenyl)amino)methylene)malonate (3)
—6-Amino-2,3-difluorophenol (2) (550 mg, 3.8 mmol) was dissolved in ethanol (15 mL)
and diethyl 2-(ethoxymethylene)malonate (819 mg, 3.8 mmol) was added. The reaction was
stirred at room temperature until there was no starting material left. Ethanol was removed
and the residue was purified by flash column chromatography on silica gel (EtOAc / hexane
= 1 / 3 to 3 / 1) to give product 3 as a brown solid (1.04 g, 87%). 1H NMR (400 MHz, d6DMSO): δ (ppm) 10.96 (d, J = 14.0 Hz, 1H), 8.45 (d, J = 13.9 Hz, 1H), 7.31–7.22 (m, 1H),
6.98–6.86 (m, 1H), 4.20 (q, J = 7.1 Hz, 2H), 4.12 (q, J = 7.1 Hz, 2H), 1.26 (t, J = 7.1 Hz,
3H), 1.24 (t, J = 7.1 Hz, 3H). ESI-MS: calc. for C14H14F2NO5 [M − H]−: 314.3, found:
314.3.

Author Manuscript

4.1.3. Ethyl 6,7-difluoro-8-hydroxy-4-oxo-1,4-dihydroquinoline-3-carboxylate
(4)—Compound 3 (445 mg, 1.4 mmol) was added in a microwave sealed tube. Diphenyl
ether (2.5 mL) was added and the tube was sealed with cap. The reaction was then set up at
250 °C in a Biotage Microwave Initiator instrument for 30 min. Hexane was added and the
solid was filtered and washed with hexane. The product was then dried and obtained in 80%
yield (299.4 mg), which was used for next step without further purification. 1H NMR (400
MHz, d6-DMSO): δ (ppm) 8.36 (s, 1H), 7.45 (dd, J = 10.9, 7.9 Hz, 1H), 4.21 (q, J = 7.1 Hz,
2H), 1.27 (t, J = 7.1 Hz, 3H). ESI-MS: calc. for C12H8F2NO4 [M − H]−: 268.2, found:
268.2.
4.1.4. Ethyl 5,6-difluoro-9-nitro-3-oxo-3H–pyrido[3,2,1-kl]phenoxazine-2carboxylate (6a)—Compound 4 (269 mg, 1 mmol) and 1-chloro-2,4-dinitrobenzene (202
mg, 1 mmol) were dissolved in DMF (2 mL). NaHCO3 (252 mg, 3 mmol) was added and
the reaction was stirred at 100 °C until no starting materials were detected by HPLC. The
solid base was removed by filtration through Celite. The filtrate was concentrated and the
residue was purified through Biotage reverse phase C18 cartridge to give 220 mg of 6a as
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yellow solid (yield: 57%). 1H NMR (400 MHz, d6-DMSO): δ (ppm) 9.01 (s, 1H), 8.15 (d, J
= 9.6 Hz, 1H), 8.05–8.01 (m, 2H), 7.60–7.54 (m, 1H), 4.27 (q, J = 7.2 Hz, 2H), 1.32 (t, J =
7.2 Hz, 3H); 13C NMR (100 MHz, d6-DMSO): δ (ppm) 170.4, 163.7, 145.8, 142.7, 138.1,
133.2, 129.4, 124.6, 122.2, 120.8, 117.0, 113.0, 105.4, 105.2, 60.8, 14.2; ESI-MS: calc. for
C18H10F2N2O6Na [M + Na]+: 411.3, found: 411.2. ESI-HRMS: calc. for C18H11F2N2O6 [M
+ H]+: 389.0580, found: 389.0582. HPLC purity: 100% (254 nm), tR: 6.92 min; 100% (220
nm), tR: 6.92 min. Compounds 6b–e were prepared according to the experimental procedure
above for the preparation of 6a.

Author Manuscript

4.1.5. Ethyl 9-cyano-5,6-difluoro-3-oxo-3H–pyrido[3,2,1-kl]phenoxazine-2carboxylate (6b)—Yellow solid. Yield: 59%. 1H NMR (400 MHz, d6-DMSO): δ (ppm)
9.04 (s, 1H), 8.11 (d, J = 8.8 Hz, 1H), 7.87 (d, J = 1.6 Hz, 1H), 7.72 (dd, J = 1.6 and 8.8 Hz,
1H), 7.63–7.59 (m, 1H), 4.28 (q, J = 7.2 Hz, 2H), 1.31 (t, J = 7.2 Hz, 3H); ESI-MS: calc. for
C19H10F2N2O4Na [M + Na]+: 391.3, found: 391.2. ESI-HRMS: calc. for C19H11F2N2O4 [M
+ H]+: 369.0681, found: 369.0684. HPLC purity: 100% (254 nm), tR: 6.73 min; 100% (220
nm), tR: 6.73 min.
4.1.6. Ethyl 5,6-difluoro-3-oxo-9-(trifluoromethyl)-3H–pyrido[3,2,1kl]phenoxazine-2-carboxylate (6c)—Yellow solid. Yield: 10%. 1H NMR (400 MHz,
d6-DMSO): δ (ppm) 9.05 (s, 1H), 8.12 (d, J = 8.8 Hz, 1H), 7.71 (d, J = 1.6 Hz, 1H), 7.63–
7.58 (m, 2H), 4.27 (q, J = 7.2 Hz, 2H), 1.32 (t, J = 7.2 Hz, 3H); ESI-MS: calc. for
C19H10F5NO4Na [M + Na]+: 434.3, found: 434.1. ESI-HRMS: calc. for C19H11F5NO4 [M +
H]+: 412.0603, found: 412.0603. HPLC purity: 100% (254 nm), tR: 7.25 min; 100% (220
nm), tR: 7.25 min.

Author Manuscript

4.1.7. Ethyl 9-acetyl-5,6-difluoro-3-oxo-3H–pyrido[3,2,1-kl] phenoxazine-2carboxylate (6d)—Dark yellow solid. Yield: 38%. 1H NMR (400 MHz, d6-DMSO): δ
(ppm) 8.97 (s, 1H), 8.06–7.93 (m, 1H), 7.73 (d, J = 8.4 Hz, 1H), 7.69 (s, 1H), 7.55 (dd, J =
10.2, 8.0 Hz, 1H), 4.27 (q, J = 7.1 Hz, 2H), 2.58 (s, 3H), 1.33 (t, J = 7.1 Hz, 3H). ESI-MS:
calc. for C20H13F2NNaO5 [M + Na]+: 408.3, found: 408.1. HPLC purity: 100% (254 nm),
tR: 6.62 min; 100% (220 nm), tR: 6.62 min.

Author Manuscript

4.1.8. Ethyl 10-chloro-5,6-dif luoro-9-nitro-3-oxo-3H–pyrido[3,2,1kl]phenoxazine-2-carboxylate (6e)—Dark yellow solid. Yield: 40%. 1H NMR (400
MHz, d6-DMSO): δ (ppm) 9.13 (s, 1H), 8.48 (s, 1H), 8.12 (s, 1H), 7.69–7.60 (m, 1H), 4.30
(q, J = 7.0 Hz, 2H), 1.33 (t, J = 7.1 Hz, 3H). ESI-MS: calc. for C18H9ClF2N2NaO6 [M +
Na]+: 445.0, found: 445.1. HPLC purity: 98.5% (254 nm), tR: 6.92 min; 96.9% (220 nm), tR:
6.92 min.
4.1.9. 5,6-Difluoro-9-nitro-3-oxo-3H–pyrido[3,2,1-kl]phenoxazine-2-carboxylic
acid (7a)—Compound 6a (180 mg, 0.46 mmol) was dissolved in AcOH (15 mL).
Hydrochloric acid (1 N, 2 mL) was added and the reaction was stirred under reflux for 2 h.
Upon completion, water was added and yellow solid was precipitated. The solid was
collected by filtration and washed with water, then dried and afforded product 7a (150 mg)
as yellow solid in 91% yield. 1H NMR (400 MHz, d6-DMSO): δ (ppm) 9.36 (s, 1H), 8.42
(d, J = 9.2 Hz, 1H), 8.17 (d, J = 2.8 Hz, 1H), 8.09 (dd, J = 2.4 and 9.2 Hz, 1H), 7.86–7.82
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Compounds 7b–e were prepared according to the experimental procedure above for the
preparation of 7a.

Author Manuscript

(m, 1H); ESI-MS: calc. for C16H7F2N2O6 [M + H]+: 361.2, found: 361.3. ESI-HRMS: calc.
for C16H7F2N2O6 [M + H]+: 361.0267, found: 361.0268. HPLC purity: 100% (254 nm), tR:
6.79 min; 100% (220 nm), tR: 6.79 min.

4.1.11. 5,6-Difluoro-3-oxo-9-(trifluoromethyl)-3H–pyrido[3,2,1kl]phenoxazine-2-carboxylic acid (7c)—Yellow solid. Yield: 95%. 1H NMR (400
MHz, d6-DMSO): δ (ppm) 9.35 (s, 1H), 8.37 (d, J = 8.4 Hz, 1H), 7.84–7.79 (m, 2H), 7.65–
7.62 (dd, J = 1.2 and 8.8 Hz, 1H); ESI-MS: calc. for C17H7F5NO4 [M + H]+: 384.2, found:
384.1. ESI-HRMS: calc. for C17H7F5NO4 [M + H]+: 384.0290, found: 384.0293. HPLC
purity: 100% (254 nm), tR: 7.15 min; 100% (220 nm), tR: 7.15 min.

4.1.10. 9-Cyano-5,6-difluoro-3-oxo-3H–pyrido[3,2,1-kl]phenoxazine-2carboxylic acid (7b)—Yellow solid. Yield: 36%. 1H NMR (400 MHz, d6-DMSO): δ
(ppm) 9.34 (s, 1H), 8.35 (d, J = 8.8 Hz, 1H), 7.98 (d, J = 1.6 Hz, 1H), 7.82 (d, J = 2.4 Hz,
1H), 7.78–7.75 (m, 2H); ESI-MS: calc. for C17H7F2N2O4 [M + H]+: 341.2, found: 341.1.
ESI-HRMS: calc. for C17H7F2N2O4 [M + H]+: 341.0368, found: 341.0378. HPLC purity:
95.1% (254 nm), tR: 6.37 min; 97.7% (220 nm), tR: 6.37 min.

Author Manuscript

4.1.12. 9-Acetyl-5,6-difluoro-3-oxo-3H–pyrido[3,2,1-kl] phenoxazine-2carboxylic acid (7d)—Yellow solid. Yield: 62%. 1H NMR (400 MHz, d6-DMSO): δ
(ppm) 9.36 (s, 1H), 8.30 (d, J = 11.2 Hz, 1H), 7.85–7.80 (m, 3H), 2.63 (s, 3H); ESI-MS:
calc. for C18H10F2NO5 [M + H]+: 358.3, found: 358.2. ESI-HRMS: calc. for C18H10F2NO5
[M + H]+: 358.0522, found: 358.0521. HPLC purity: 97.3% (254 nm), tR: 6.70 min; 97.2%
(220 nm), tR: 6.70 min.
4.1.13. 10-Chloro-5,6-difluoro-9-nitro-3-oxo-3H–pyrido[3,2,1-kl]phenoxazine-2carboxylic acid (7e)—Brown solid. Yield: 39%. 1H NMR (400 MHz, d6-DMSO): δ
(ppm) 9.43 (s, 1H), 8.74 (s, 1H), 8.18 (s, 1H), 7.83–7.79 (m, 1H); ESI-MS: calc. for
C16H6ClF2N2O6 [M + H]+: 394.7, found: 394.9. ESI-HRMS: calc. for C16H6F2N2ClO6 [M
+ H]+: 394.9877, found: 394.9879. HPLC purity: 95.4% (254 nm), tR: 6.90 min; 97.0% (220
nm), tR: 6.90 min.

Author Manuscript

4.1.14. 9-Amino-5,6-difluoro-3-oxo-3H–pyrido[3,2,1-kl]phenoxazine-2carboxylic acid (1)—Compound 7a (150 mg, 0.42 mmol) was added to a mixture of
AcOH / HCl (1 / 1). SnCl2 (236 mg, 1.25 mmol) was added and the reaction was stirred
under reflux for 2 h. No starting material was observed in the reaction and then water was
added. The large amount of solid precipitated and was collected by filtration. Product 1 was
obtained in 86% yield (236 mg) as yellow solid. 1H NMR (400 MHz, d6-DMSO): δ (ppm)
9.08 (s, 1H), 7.79 (d, J = 9.2 Hz, 1H), 7.76–7.73 (m, 1H), 6.48 (dd, J = 2.4 and 9.2 Hz, 1H),
6.43 (d, J = 2.4 Hz, 1H); ESI-MS: calc. for C16H9F2N2O4 [M + H]+: 331.3, found: 331.1.
ESI-HRMS: calc. for C16H9F2N2O4 [M + H]+: 331.0525, found: 331.0526. HPLC purity:
100% (254 nm), tR: 6.47 min; 100% (220 nm), tR: 6.47 min.
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4.1.15. Ethyl-5-fluoro-6-(4-m ethylpiperazin-1-yl)-9-nitro-3-oxo-3H–pyrido[3,2,1kl]phenoxazine-2-carboxylate (9)—Compound 6a (159 mg, 0.4 mmol) was dissolved
in pyridine (1 mL) and 1-methylpiperazine (120 mg, 1.2 mmol) was added. The reaction was
heated to 110 °C until no starting material was observed. Pyridine was removed under
reduced pressure and the residue was purified by flash column chromatography on silica gel
(MeOH / CH2Cl2 = 1 / 19), affording product 9 (100.1 mg) in 53% yield as orange solid. 1H
NMR (400 MHz, d6-DMSO): δ (ppm) 8.87 (d, J = 1.6 Hz, 1H), 8.04–7.97 (m, 2H), 7.87 (t, J
= 1.2 Hz, 1H), 7.32 (dd, J = 1.2 and 8.0 Hz, 2H), 4.25 (q, J = 7.2 Hz, 2H), 3.34 (s, 4H), 3.27
(s, 4H), 2.27 (s, 3H), 1.32 (t, J = 7.2 Hz, 3H); ESI-MS: calc. for C23H22FN4O6 [M + H]+:
469.4, found: 469.3. HPLC purity: 100% (254 nm), tR: 5.48 min; 100% (220 nm), tR: 5.48
min.

Author Manuscript
Author Manuscript

4.1.16. 5-Fluoro-6-(4-methylpiperazin-1-yl)-9-nitro-3-oxo-3H–pyrido[3,2,1kl]phenoxazine-2-carboxylic acid (10a)—Compound 7a (108 mg, 0.3 mmol) was
dissolved in pyridine (4 mL), and then the reaction was heated to 90 °C. 1-Methylpiperazine
(100 µL, 0.9 mmol) was added and the reaction was stirred under nitrogen atmosphere until
there was no starting material. Upon completion, pyridine was removed under reduced
pressure and the residue was dissolved in ethanol (10 mL) and heated under reflux for
additional 30 min. The solid was filtered and washed with water, then dried to obtain
product 10a (60 mg) in 45 % yield as yellow solid. 1H NMR (400 MHz, d6-DMSO): δ
(ppm) 9.18 (s, 1H), 8.29 (d, J = 8.0 Hz, 1H), 8.02–7.99 (m, 2H), 7.53 (d, J = 12.6 Hz, 1H),
3.30 (br s, overlapping with H2O peak, 4H), 2.57 (br s, 4H), 2.32 (s, 3H); ESI-MS: calc. for
C21H18FN4O6 [M + H]+: 441.4, found: 441.4. ESI-MS: calc. for C21H18FN4O6 [M + H]+:
441.1205, found: 441.1216. HPLC purity: 100% (254 nm), tR: 5.37 min; 100% (220 nm), tR:
5.37 min. Compounds 10b and 11a–k were prepared following the similar procedure for the
preparation of 10a.
4.1.17. 5-Fluoro-9-nitro-3-oxo-6-(piperazin-1-yl)-3H–pyrido[3,2,1kl]phenoxazine-2-carboxylic a ci d (10b)—Yellow solid. Yield: 84%. 1H NMR (400
MHz, d6-DMSO): δ (ppm) 8.94 (s, 1H), 7.66 (d, J = 8.8 Hz, 1H), 7.45 (d, J = 12.0 Hz, 1H),
6.43–6.36 (m, 2H), 3.22 (s, 4H), 2.87 (s, 4H); ESI-MS: calc. for C20H16FN4O6 [M + H]+:
427.4, found: 427.2. ESI-HRMS: calc. for C20H16FN4O6 [M + H]+: 427.1048, found:
427.1041. HPLC purity: 100% (254 nm), tR: 5.36 min; 100% (220 nm), tR: 5.36 min.

Author Manuscript

4.1.18. 9-Amino-5-fluoro-6-(4-methylpiperazin-1-yl)-3-oxo-3H–pyrido[3,2,1kl]phenoxazine-2-carboxylic acid (11a)—Yellow solid. Yield: 48%. 1H NMR (400
MHz, d6-DMSO): δ (ppm) 8.94 (s, 1H), 7.65 (d, J = 9.2 Hz, 1H), 7.45 (d, J = 12.0 Hz, 1H),
6.43–6.36 (m, 2H), 5.77 (s, 2H), 3.31 (s, 4H), 2.57 (s, 4H), 2.32 (s, 3H); ESI-MS: calc. for
C21H20FN4O4 [M + H]+: 411.4, found: 411.2. ESI-MS: calc. for C21H20FN4O4 [M + H]+:
411.1463, found: 411.1466. HPLC purity: 100% (254 nm), tR: 5.22 min; 100% (220 nm), tR:
5.22 min.
4.1.19. 9-Amino-5-fluoro-3-oxo-6-(piperazin-1-yl)-3H–pyrido[3,2,1kl]phenoxazine-2-carboxylic acid (11b)—Yellow solid. Yield: 97%. 1H NMR (400
MHz, d6-DMSO): δ (ppm) 8.97 (s, 1H), 7.68 (d, J = 9.2 Hz, 1H), 7.48 (d, J = 12.4 Hz, 1H),
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6.44–6.38 (m, 2H), 5.77 (s, 2H), 3.22 (s, 4H), 2.86 (s, 4H); ESI-MS: calc. for C20H18FN4O4
[M + H]+: 397.4, found: 397.2. ESI-HRMS: calc. for C20H18FN4O4 [M + H]+: 397.1307,
found: 397.1303. HPLC purity: 100% (254 nm), tR: 5.20 min; 100% (220 nm), tR: 5.20 min.
4.1.20. 9-Amino-5-fluoro-6-(4-methylpiperidin-1-yl)-3-oxo-3H–pyrido[3,2,1kl]phenoxazine-2-carboxylic acid (11c)—Yellow solid. Yield: 33%. 1H NMR (400
MHz, d6-DMSO): δ (ppm) 8.92 (s, 1H), 7.63 (d, J = 8.0 Hz, 1H), 7.43 (d, J = 11.6 Hz, 1H),
6.42–6.36 (m, 2H), 5.75 (s, 2H), 3.13 (t, J = 10.8 Hz, 2H), 1.71 (d, J = 11.2 Hz, 2H), 1.57 (s,
1H), 1.32–1.26 (m, 2H), 0.98 (s, 3H); 13C NMR (100 MHz, d6-DMSO): δ (ppm) 175.4,
166.4, 150.7, 144.6, 138.5, 136.0, 131.7, 125.3, 119.6, 119.5, 117.6, 112.2, 111.1, 107.0,
104.0, 101.2, 51.1, 35.1, 30.6, 22.5; ESI-MS: calc. for C22H21FN3O4 [M + H]+: 410.4,
found: 410.2. ESI-HRMS: calc. for C22H21FN3O4 [M + H]+: 410.1511, found: 410.1510.
HPLC purity: 100% (254 nm), tR: 6.38 min; 100% (220 nm), tR: 6.38 min.

Author Manuscript

4.1.21. 9-Amino-5-fluoro-6-morpholino-3-oxo-3H–pyrido[3,2,1kl]phenoxazine-2-carboxylic acid (11d)—Yellow solid. Yield: 71%. 1H NMR (400
MHz, d6-DMSO): δ (ppm) 8.93 (s, 1H), 7.64 (d, J = 8.8 Hz, 1H), 7.45 (d, J = 12.0 Hz, 1H),
6.43–6.37 (m, 2H), 5.75 (s, 2H), 3.69 (s, 4H), 3.28 (s, 4H); ESI-MS: calc. for C20H17FN3O5
[M + H]+: 398.4, found: 398.2. ESI-HRMS: calc. for C20H17FN3O5 [M + H]+: 398.1147,
found: 398.1146. HPLC purity: 100% (254 nm), tR: 6.38 min; 100% (220 nm), tR: 6.38 min.

Author Manuscript

4.1.22. 9-Amino-5-fluoro-3-oxo-6-(phenethylamino)-3H–pyrido[3,2,1kl]phenoxazine-2-carboxylic acid (11e)—Yellow solid. Yield: 55%. 1H NMR (400
MHz, d6-DMSO): δ (ppm) 8.90 (s, 1H), 7.61 (d, J = 9.2 Hz, 1H), 7.45 (d, J = 13.2 Hz, 1H),
7.29–7.18 (m, 5H), 6.43–6.37 (m, 2H), 6.15 (br s, 1H), 5.76 (br s, 2H), 3.68–3.61 (m, 2H),
2.89–2.85 (m, 2H); ESI-MS: calc. for C24H18FN3O4 [M + H]+: 432.4, found: 432.1. ESIHRMS: calc. for C24H19FN3O4 [M + H]+: 432.1354, found: 432.1362. HPLC purity: 100%
(254 nm), tR: 7.07 min; 100% (220 nm), tR: 7.07 min.
4.1.23. 6-(((3s,5s,7s)-Adamantan-1-yl)amino)-9-amino-5-fluoro-3-oxo-3H–
pyrido[3,2,1-kl]phenoxazine-2-carboxylic acid (11f)—Brown solid. Yield: 29%. 1H
NMR (400 MHz, d6-DMSO): δ (ppm) 9.00 (s, 1H), 7.71 (d, J = 9.1 Hz, 1H), 7.54 (d, J =
10.7 Hz, 1H), 6.50–6.38 (m, 2H), 5.81 (s, 2H), 4.34 (s, 1H), 2.09–2.04 (m, 3H), 1.85 (s, 6H),
1.65–1.55 (m, 6H). ESI-MS: calc. for C26H23FN3O4 [M − H]+: 460.2, found: 460.0. HPLC
purity: 85.2% (254 nm), tR: 7.41 min; 91.1% (220 nm), tR: 7.41 min.

Author Manuscript

4.1.24. 6-([1,4’-Bipiperidin]-1’-yl)-9-amino-5-fluoro-3-oxo-3H–pyrido[3,2,1kl]phenoxazine-2-carboxylic acid (11g)—Yellow solid. Yield: 64%. 1H NMR (400
MHz, d6-DMSO): δ (ppm) 8.98 (s, 1H), 7.68 (d, J = 4.0 Hz, 1H), 7.49 (d, J = 9.6 Hz, 1H),
6.45–6.41 (m, 2H), 5.77 (br s, 2H), 3.20–3.15 (m, 1H), 1.84–1.82 (m, 3H), 1.64–1.41 (m,
14H), 1.06–1.04 (m, 1H); ESI-MS: calc. for C26H28FN4O4 [M + H]+: 479.5, found: 479.3.
ESI-HRMS: calc. for C26H28FN4O4 [M + H]+: 479.2089, found: 479.2093. HPLC purity:
100% (254 nm), tR: 5.53 min; 100% (220 nm), tR: 5.53 min.
4.1.25. 9-Amino-5-fluoro-6-((2-morpholinoethyl)amino)-3-oxo-3H–pyrido[3,2,1kl]phenoxazine-2-carboxylic acid (11h)—Yellow solid. Yield: 74%. 1H NMR (400
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MHz, d6-DMSO): δ (ppm) 8.90 (s, 1H), 8.55 (s, 1H), 7.46 (d, J = 6.0 Hz, 1H), 7.39–7.34
(m, 2H), 6.42–6.37 (m, 2H), 5.95 (s, 1H), 5.78 (br s, 2H), 2.57 (s, 2H), 2.44 (br s, 6H); ESIMS: calc. for C22H22FN4O5 [M + H]+: 441.4, found: 441.3. ESI-MS: calc. for
C22H22FN4O5 [M + H]+: 441.1569, found: 441.1579. HPLC purity: 97.2% (254 nm), tR:
5.22 min; 99.3% (220 nm), tR: 5.22 min.
4.1.26. 9-Amino-6-(cyclohexylamino)-5-fluoro-3-oxo-3H–pyrido[3,2,1kl]phenoxazine-2-carboxylic acid (11i)—Brown solid. Yield: 74%. 1H NMR (400
MHz, d6-DMSO): δ (ppm) 8.86 (s, 1H), 7.58–7.56 (m, 1H), 7.43–7.40 (m, 1H), 6.40 (s,
1H), 5.72 (s, 2H), 5.40–5.38 (m, 1H), 1.92 (s, 3H), 1.73–1.67 (m, 3H), 1.31–1.22 (m, 6H);
ESI-MS: calc. for C22H21FN3O4 [M + H]+: 410.4, found: 410.3. ESI-HRMS: calc. for
C22H21FN3O4 [M + H]+: 410.1511, found: 410.1494. HPLC purity: 100% (254 nm), tR:
7.27 min; 100% (220 nm), tR: 7.27 min.

Author Manuscript

4.1.27. 9-Amino-6-(cyclopentylamino)-5-fluoro-3-oxo-3H–pyrido[3,2,1kl]phenoxazine-2-carboxylic acid (11j)—Black solid. Yield: 63%. 1H NMR (400
MHz, d6-DMSO): δ (ppm) 8.91 (s, 1H), 7.62 (d, J = 8.8 Hz, 1H), 7.47 (d, J = 12.4 Hz, 1H),
6.46–6.41 (m, 2H), 5.73 (s, 2H), 5.53 (d, J = 2.4 Hz, 1H), 4.30 (s, 1H), 1.93 (br s, 4H), 1.73
(br s, 4H); ESI-MS: calc. for C21H19FN3O4 [M + H]+: 396.4, found: 396.1. ESI-HRMS:
calc. for C21H19FN3O4 [M + H]+: 396.1354, found: 396.1358. HPLC purity: 96.7% (254
nm), tR: 7.07 min; 96.0% (220 nm), tR: 7.06 min.
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4.1.28. 9-Amino-5-fluoro-6-(hexylamino)-3-oxo-3H–pyrido[3,2,1kl]phenoxazine-2-carboxylic acid (11k)—Yellow solid. Yield: 49%. 1H NMR (400
MHz, d6-DMSO): δ (ppm) 8.88 (s, 1H), 7.64 (s, 1H), 7.44 (s, 1H), 6.56–6.36 (m, 2H), 5.88–
5.50 (m, 2H), 1.57 (s, 2H), 1.27 (s, 7H), 0.84 (s, 4H); ESI-MS: calc. for C22H23FN3O4 [M +
H]+: 412.4, found: 412.2. ESI-HRMS: calc. for C22H23FN3O4 [M + H]+: 412.1667, found:
412.1672. HPLC purity: 100% (254 nm), tR: 7.47 min; 100% (220 nm), tR: 7.47 min.
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4.1.29. 9-acetamido-5,6-difluoro-3-oxo-3H–pyrido[3,2,1-kl]phenoxazine-2carboxylic acid (12)—To the solution of 1 (33 mg, 0.1 mmol) and pyridine (1 mL), acetic
anhydride (12.2 mg, 0.12 mmol) was added. The reaction was stirred at 80 °C for 3 h, then
at 100 °C until no starting material was detected by HPLC. The solid was filtered and dried
to give 34.1 mg of 12 in 92% yield. Yellow solid. 1H NMR (400 MHz, d6-DMSO): δ (ppm)
10.31 (s, 1H), 9.20 (s, 1H), 8.05 (d, J = 9.2 Hz, 1H), 7.78 (t, J = 8.0 Hz, 1H), 7.66 (s, 1H),
7.29 (d, J = 7.6 Hz, 1H), 2.06 (s, 3H); ESI-MS: calc. for C18H11F2N2O5 [M + H]+: 373.3,
found: 373.2. ESI-MS: calc. for C18H11F2N2O5 [M + H]+: 373.0631, found: 373.0638.
HPLC purity: 98.6% (254 nm), tR: 6.42 min; 99.1% (220 nm), tR: 6.42 min. Compounds 14
and 15a–b were prepared at 70 °C following the similar procedure for the preparation of 10a
4.1.30. (S)-9-amino-6-(3-((tert-butoxycarbonyl)amino)pyrrolidin-1-yl)-5-fluoro-3oxo-3H–pyrido[3,2,1-kl]phenoxazine-2-carboxylic acid (15a)—Yellow solid. Yield:
86%. 1H NMR (400 MHz, d6-DMSO): δ (ppm) 8.77 (s, 1H), 7.49 (d, J = 9.6 Hz, 1H), 7.31
(d, J = 14.0 Hz, 1H), 7.17 (d, J = 5.6 Hz, 1H), 6.38 (dd, J = 2.4 and 9.2 Hz, 2H), 6.29 (d, J =
2.0 Hz, 1H), 5.67 (s, 2H), 3.82–3.80 (m, 5H), 2.05–2.04 (m, 1H), 1.83 (br s, 1H), 1.38 (s,
9H); ESI-MS: calc. for C25H26FN4O6 [M + H]+: 497.5, found: 497.3. ESI-HRMS: calc. for
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C25H26FN4O6 [M + H]+: 497.1831, found: 497.1831. HPLC purity: 100% (254 nm), tR:
6.94 min; 100% (220 nm), tR: 6.94 min.
4.1.31. (S)-6-(3-aminopyrroli din-1-yl)-5-fluoro-9-nitro-3-oxo-3H–pyrido[3,2,1-kl]
phenoxazine-2-carboxyl ic acid (16)—Compound 16 was prepared following the same
procedure for the synthesis of 7. Brown solid. Yield: 32% (two steps). 1H NMR (400 MHz,
d6-DMSO): δ (ppm) 9.10 (s, 1H), 8.41 (s, 2H), 8.25 (d, J = 9.3 Hz, 1H), 8.09 (s, 1H), 8.01
(d, J = 7.2 Hz, 1H), 7.48 (d, J = 13.6 Hz, 1H), 4.07 – 3.74 (m, 5H), 2.28 (s, 1H), 2.08 (s,
1H). ESI-MS: calc. for C20H16FN4O6 [M + H]+: 427.4, found: 427.1. HPLC purity: 100%
(254 nm), tR: 5.45 min; 100% (220 nm), tR: 5.46 min.
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4.1.32. (S)-9-amino-6-(3-aminopyrrolidin-1-yl)-5-fluoro-3-oxo-3H–pyrido[3,2,1kl]phenoxazine-2-carboxylic acid (17a)—Compound 15a (85 mg, 0.17 mmol) was
dissolved in 10 mL of hydrochloric acid (1 N). The reaction was stirred under reflux for 2.5
h. The solvent was removed and ethanol (10 mL) was added. The mixture was heated under
reflux for 30 min. The solid was collected by filtration and dried to yield 52 mg of 17a in
78% yield. Yellow solid. 1H NMR (400 MHz, d6-DMSO): δ (ppm) 8.94 (s, 1H), 8.24 (s,
3H), 7.65 (d, J = 9.2 Hz, 1H), 7.50 (d, J = 13.6 Hz, 1H), 6.46–6.40 (m, 2H), 3.99–3.85 (m,
5H), 2.34–2.26 (m, 1H), 2.09–1.98 (m, 1H); ESI-MS: calc. for C20H18FN4O4 [M + H]+:
397.4, found: 397.1. ESI-MS: calc. for C20H18FN4O4 [M + H]+: 397.1307, found: 397.1298.
HPLC purity: 100% (254 nm), tR: 5.20 min; 100% (220 nm), tR: 5.20 min.
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4.1.33. (R)-9-amino-6-(3-aminopyrrolidin-1-yl)-5-fluoro-3-oxo-3H–pyrido[3,2,1kl]phenoxazine-2-carboxylic acid (17b)—Compound 17b was prepared using the
same procedure for the synthesis of 17a. Brown solid. Yield: 48% (two steps). 1H NMR
(400 MHz, d6-DMSO): δ (ppm) 8.88 (s, 1H), 8.31 (s, 3H), 7.59 (d, J = 9.2 Hz, 1H), 7.43 (d,
J = 13.2 Hz, 1H), 6.42 (d, J = 9.2 Hz, 1H), 6.38 (s, 1H), 3.98–3.88 (m, 2H), 3.73–3.68 (m,
3H), 2.30–2.25 (m, 1H), 2.06–2.03 (m, 1H); ESI-MS: calc. for C20H18FN4O4 [M + H]+:
397.4, found: 397.2. ESI-HRMS: calc. for C20H18FN4O4 [M + H]+: 397.1307, found:
397.1302. HPLC purity: 100% (254 nm), tR: 5.24 min; 100% (220 nm), tR: 5.24 min.
4.2. Target-based biochemical assays
Topoisomerase enzymes—Recombinant E. coli topoisomerase I and gyrase expressed
in E. coli were purified as described previously [24, 25]. Human topoisomerase I and
topoisomerase IIα were purchased from TopoGen (Buena vista, CO, USA).

Author Manuscript

4.2.1. E. coli topoisomerase I relaxation activity inhibition assay—The relaxation
activity of E. coli topoisomerase I was assayed in a buffer containing 10 mM Tris-HCl, pH
8.0, 50 mM NaCl, 0.1 mg/mL gelatin, and 0.5 mM MgCl2. Half microliter from the
appropriate stock solutions of compounds dissolved in the solvent (DMSO) or the solvent
alone (control) was mixed with 9.5 µL of the reaction buffer containing 10 ng of enzyme
before the addition of 10 µL of reaction buffer containing 200 ng of supercoiled pBAD/Thio
plasmid DNA purified by cesium chloride gradient as substrate. Following incubation at
37 °C for 30 min, the reactions were terminated by the addition of 4 µL of a stop buffer
(50% glycerol, 50 mM EDTA, and 0.5% (v/v) bromophenol blue), and analyzed by agarose
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gel electrophoresis. The gels were stained in ethidium bromide and photographed under UV
light.
4.2.2. DNA gyrase supercoiling inhibition assay—DNA gyrase supercoiling assays
were carried out by mixing the compounds and the enzyme in a similar manner as above
(EcTopI relaxation inhibition assay) but in a gyrase assay buffer (35 mM Tris-HCl, 24 mM
KCl, 4 mM MgCl2, 2 mM DTT, 1.75 mM ATP, 5 mM spermidine, 0.1 mg/mL BSA, 6.5 %
glycerol at pH 7.5), followed by the addition of 300 ng of relaxed covalently closed circular
DNA (New England Biolabs, Ipswich, MA, USA) to a final reaction volume of 20 µL. The
samples were incubated at 37 °C for 30 minutes before being terminated by the addition of a
buffer containing 5% SDS, 0.25% bromophenol blue, and 25% glycerol. The reactions were
then analyzed by agarose gel electrophoresis.
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4.2.3. Human topoisomerase I relaxation inhibition assay—Human topoisomerase
I relaxation assays were carried out with 0.5 U of enzyme in reaction buffer supplied by the
manufacturer. The enzyme was mixed with the indicated concentration of compound
dissolved before 200 ng of supercoiled pBAD/Thio plasmid DNA was added in the same
buffer, for a final volume of 20 µL. Following incubation at 37 °C for 30 minutes, the
reactions were terminated with a buffer containing 5% SDS, 0.25% bromophenol blue, and
25% glycerol, and analyzed by agarose gel electrophoresis.
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4.2.4. Human topoisomerase IIα decatenation inhibition assay—Human
Topoisomerase IIα assays were carried out by adding the compounds to 185 ng of
kinetoplast DNA (kDNA, from TopoGen) in the buffer supplied by the manufacturer before
the addition of 2 U of the enzyme. The samples were incubated for 15 minutes at 37 °C
before the addition of 4 µL of a stop buffer containing 5% sarkosyl, 0.25% bromophenol
blue, and 25% glycerol. The reactions were then analyzed by electrophoresis in 1% agarose
gels containing 0.5 µg/mL ethidium bromide before being photographed under UV light.
4.3. Cell-based assays
The minimum inhibitory concentrations (MIC) of the compounds were determined against
E. coli and B. subtilis in cation-adjusted Mueller-Hinton Broth according to standard
microdilution protocol [26].
MICs of compounds against M. tuberculosis were determined by a modified microplate
Alamar blue assay (MABA) [27]. Vero cell cytotoxicity assay was performed as previously
described [27].
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4.4. CoMFA modeling
4.4.1. Dataset—All the synthesized and tested fluoroquinophenoxazine derivatives were
used for CoMFA study. The topoisomerase I inhibitory activity (IC50, µM) from biochemical
enzyme assay was converted to pIC50 values for correlation purpose (pIC50 = – logIC50).
The total compound set is divided into two subsets: a training set of 21 compounds for
generating 3D-QSAR models and a test set of 7 compounds for validating the quality of the
model (Table 2). The compound selections of training and test sets were done manually so
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that compounds ranging from weak, moderate, to strong topoisomerase I inhibitory activities
were present in both sets and were in approximately equal proportions.
4.4.2. Conformational model analysis and molecular alignment—In the 3DQSAR studies, alignment rule and biological conformation selection are two important
factors to construct reliable models. For both training and test set molecules, conformational
models representing their available conformational space were calculated. All the molecules
were subjected to produce a maximum of 255 conformations within 20 kcal/mol in energy
from global minimum. Due to the relatively rigid structural feature of these molecules, the
core structure of quinophenoxazine was used for the alignment.

Author Manuscript

4.4.3. CoMFA model generation—CoMFA was performed using the QSAR module of
SYBYL-X [28]. The steric and electrostatic field energies were calculated using the
Lennard-Jones and the Coulomb potentials, respectively, with a 1/r distance-dependent
dielectric constant in all intersections of a regularly spaced (0.2 nm) grid. The electrostatic
fields were computed using Gasteiger-Huckel charge calculation methods. A sp3 hybridized
carbon atom with a radius of 1.53 Å and a charge of +1.0 was used as a probe to calculate
the steric and electrostatic energies between the probe and the molecules using the Tripos
force field. The standard parameters implemented in SYBYL-X were used. The truncation
for both steric and electrostatic energies was set to 30 kcal/mol.
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4.4.4. Partial least square (PLS) analysis—PLS methodology [29] was used for 3DQSAR analysis. The cross-validation analysis [30, 31] was performed using the leave one
out (LOO) methods in which one compound is removed from the dataset and its activity is
then predicted using the model derived from the rest of the dataset. The cross validated r2
that resulted in the optimum number of components and the lowest standard error of
prediction were considered for further analysis. To speed up the analysis and reduce noise, a
minimum filter value of 2.00 kcal/mol was used. A final analysis was performed to calculate
conventional r2 using the optimum number of components obtained from the crossvalidation analysis.

Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Highlights
•

Fluoroquinophenoxazines were synthesized as bacterial topoisomerase
IA inhibitors.

•

Some derivatives showed excellent inhibitory activity against
topoisomerase IA.

•

CoMFA analysis was performed to investigate the 3D-QSAR of this
chemical series.

•

The constructed CoMFA model produced reasonable and good
statistics.

Author Manuscript
Author Manuscript
Author Manuscript
Eur J Med Chem. Author manuscript; available in PMC 2018 January 05.

Yu et al.

Page 21

Author Manuscript
Author Manuscript

Fig. 1.

Chemical structures of clinical fluoroquinolone antibiotics and fluoroquinophenzoxazine
derivatives including our topo I inhibitor 1.
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Fig. 2.

SAR toward E. coli topoisomerase I inhibition.
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Fig. 3.

Inhibition of E. coli topoisomerase relaxation activity by representative 11a and 11b. A) E.
coli topoisomerase I inhibition assays with supercoiled plasmid DNA. B) E. coli DNA
gyrase inhibition assays with relaxed plasmid DNA. C: DMSO control; Nor: Norfloxacin
(125 µM) control; S: Supercoiled plasmid DNA; N: Nicked DNA; FR: Fully relaxed DNA;
PR: Partially relaxed DNA.
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Fig. 4.

The correlation chart of experimental versus predicted values for the training and test set
compounds.
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Fig. 5.
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Representative CoMFA steric and electrostatic contour maps. A). Steric contour maps with
6c; B). Steric contour maps with 11b; C). Electrostatic contour maps with 6c; and D)
Electrostatic contour maps with 11b.
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Scheme 1.

Synthesis of 9-amino-5, 6-difluoro-3-oxo-3H–pyrido[3,2,1-kl] phenoxazine-2-carboxylic
acid (1).
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Scheme 2.

Synthesis of fluoroquinophenoxazine derivatives 7b–e.
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Scheme 3.

Synthesis of diverse amino-substituted fluoroquinophenoxazines 9–11 and acetyl-protected
quinophenoxazine 12.
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Scheme 4.

Synthesis of fluoroquinophenoxazine chiral amine derivatives 16 and 17.
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12.5

25–50

0.19

0.78

25

0.78

>200

0.78

50

3.12

>200

25

>200

12.5

>200

200

25

6.25

>50

21.6

2.5

38.4

3.5

29.5

7.6

19

29

11.2

M
tuberculosis
(H37Rv)

6a

B. subtilis
(ATCC 6633)
WT

1

E. coli
(MG1655)
WT

E. coli
Imp4213
(BAS3023)

Human
topo IIα
(type IIA)

E. coli
DNA gyrase
(type IIA)

E. coli
topo I
(type IA)

Compd

Human
topo I
(type IB)

Whole cell based antibacterial activity (MIC, µM)

Topoisomerase inhibitory activity (IC50, µM)

>50

43.0

24.4

30.7

24.7

>126

29

95

>127

75.7

Vero cell
IC50

2.0

9.8

0.8

7.1

>4.3

3.8

5.0

>4.4

6.8

SIb

E. coli topoisomerase I inhibition and whole cell antibacterial activities (µM) of fluoroquinophenoxazine derivativesa
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3.9

3.9
3.9

0.97–1.95
6.25

Selectivity index = cytotoxic IC50 against Vero cells/MIC against M. tuberculosis.

Blank cells indicate Not Determined.

b

a

3.9

1.56

3.9

0.48–0.97

>200

>200
12.5

6.25
>63.1

>63.1

M
tuberculosis
(H37Rv)

0.48–0.97

B. subtilis
(ATCC 6633)
WT

17b

E. coli
(MG1655)
WT

17a

Human
topo IIα
(type IIA)

E. coli
Imp4213
(BAS3023)

Human
topo I
(type IB)

E. coli
DNA gyrase
(type IIA)

E. coli
topo I
(type IA)
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Whole cell based antibacterial activity (MIC, µM)

>63.1

>63.1

Vero cell
IC50
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7b

7c

7e

9

10a

10b

11a

11b

11d

11e

11f

11g

11h

11k

15a

16

17b

6a

7d

11c

11i

11j

12

17a

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

6c

3

7a

6b

2

5

1

1

4

Compd.

Entry
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0.73

7.8

3.9

3.9

3.9

15.6

15.6

0.73

0.48

3.9

15.6

0.97

0.48

5.85

3.9

0.97

0.24

0.48

3.9

1.95

1.95

31.25

250

31.25

15.6

250

31.25

1.95

IC50 (µM)

6.14

5.11

5.41

5.41

5.41

4.81

4.81

6.14

6.32

5.41

4.81

6.01

6.31

5.23

5.41

6.01

6.62

6.32

5.41

5.71

5.71

4.51

3.61

4.51

4.81

3.60

4.51

5.71

pIC50

5.95

4.56

5.45

5.23

5.76

4.77

4.55

5.89

5.88

5.77

5.50

5.72

6.15

5.39

5.83

5.94

6.06

6.21

5.90

6.05

5.88

4.54

4.15

4.27

4.63

4.00

4.21

5.05

CoMFA PAb

0.19

0.55

−0.04

0.18

−0.35

0.04

0.26

0.25

0.44

−0.36

−0.69

0.29

0.16

−0.16

−0.42

0.07

0.56

0.11

−0.49

−0.34

−0.17

−0.03

−0.54

0.24

0.18

−0.40

0.30

0.66

Δc

Experimental (pIC50) and CoMFA predicted activity (PA) values and residuals for the training and test set compoundsa
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Residual of experimental and predicted activity values.

c

Predicted activity.

b

Entries 1–21 for training set; entries 22–28 for test set.
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